CAR-T

Showing 15 posts of 59 posts found.

European approval for Kite’s CAR-T therapy Tecartus in elapsed or refractory mantle cell lymphoma

December 17, 2020
Sales and Marketing CAR-T, Europe, Gilead, Kite, Tecartus

Gilead-owned Kite Therapeutics has secured marketing authorisation from the European Commission for its chimeric antigen receptor (CAR) T cell therapy …

kymriah

Novartis unveils new multi-trial data for CAR-T therapy Kymriah in advanced lymphoma

December 7, 2020
Research and Development, Sales and Marketing CAR-T, Kymriah, Novartis

Novartis has taken the opportunity at the 2020 American Society of Hematology Annual Meeting & Exposition (ASH) to unveil promising …

shutterstock_3

EMA’s CHMP recommends conditional approval for Kite Pharma’s CAR T therapy for mantle cell lymphoma

October 20, 2020
Manufacturing and Production, Sales and Marketing CAR T, CAR-T, CHMP, EMA, kite pharma, lymphoma

Kite Pharma’s anti-CD19 chimeric antigen receptor (CAR) T cell therapy known as KTE-X19 has received positive recommendation from the EMA’s …

spotlighton-aprile-cw_covid-19-and-cancer-1-img

Oncology research in the age of COVID-19

September 14, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, feature, pharma

Matt Fellows investigates the new challenges facing the oncology space and explores the strategies that can carry it through the disruptive …

covidgenome

FDA approves Phase 1 trial for HIV gene therapy

August 24, 2020
Sales and Marketing CAR T, CAR T cancer therapies, CAR-T

The FDA has approved a request from American Gene Technologies to begin a clinical study into its HIV gene therapy. …

fda

Poseida suspends CAR T therapy trial in prostate cancer due to patient death

August 18, 2020
Manufacturing and Production, Research and Development CAR T, CAR-T, Poseida, patient death, pharma

Poseida’s Phase 1 trial that used an investigational CAR T therapy for treating prostate cancer has been suspended due to …

1

CAR T cell therapy is revolutionising cancer treatment, but at what cost?

August 3, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, feature

CAR T cell therapy is one of the latest innovations in gene therapy. The process is primarily used to treat …

fdaoutsideweb

Kite secures FDA approval for second CAR T therapy Tecartus in relapsed or refractory mantle cell lymphoma

July 27, 2020
Sales and Marketing CAR T, CAR-T, FDA, Gilead, kite pharma

Kite Pharma has chalked up another regulatory success for its parent company Gilead with the news that the FDA has …

janssen_latest_logo_on_sign_closer

100% of multiple myeloma patients respond to Janssen’s investigational CAR T therapy, data shows

May 14, 2020
Research and Development CAR T, CAR-T, Janssen, multiple myeloma, pharma

Janssen has revealed new Phase1b/2 findings of the efficacy of its investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell …

shutterstock

Scorpion venom added to CAR-T therapy increases efficacy in brain cancer, research shows

March 6, 2020
Medical Communications, Research and Development CAR-T, Cancer, brain cancer, glioblastoma, pharma

Chimeric antigen receptor T cell (CAR-T) therapy has gained much traction and attention in the past years for its innovative …

jj

J&J’s CAR-T candidate boasts 100% response rate in relapsed or refractory multiple myeloma

December 9, 2019
Research and Development, Sales and Marketing ASH 2019, CAR-T, J&J, JJ, Johnson & Johnson, pharma

Johnson & Johnson were present at the American Society of Hematology (ASH) Annual Meeting over the weekend to unveil new …

gilead-sciences

Gilead’s CAR-T therapy Yescarta now available via NHS Scotland for two forms of B-cell lymphoma

October 8, 2019
Manufacturing and Production, Sales and Marketing CAR T, CAR-T, NHS, Scotland, Scottish Medicines Consortium, pharma

News has broken that the Scottish Medicines Consortium (SMC) has chosen to approve the use of Gilead’s chimeric antigen receptor …

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

August 9, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, CAR T, CAR-T, Eli Lilly, Lexicon, Medicare, Novartis, Pfizer, Sanofi, pharma

This week’s top story covered the scandal surrounding Novartis over its covering up of faulty data from the FDA. The …

novartis_window

Novartis’ Kymriah to be covered by Japan’s national insurance system

May 16, 2019
Medical Communications, Sales and Marketing CAR T, CAR-T, Japan, Kymriah, Novartis, pharma

Japan’s national medical insurance system will pay for Novartis’ CAR-T therapy Kymriah following approval from the Central Social Insurance Medical …

Gilead subsidiary Kite Pharma to open CAR-T manufacturing facility in Maryland

April 29, 2019
Manufacturing and Production, Sales and Marketing CAR-T, Gilead, Manufacturing Facility, Maryland, kite pharma

Gilead Sciences subsidiary Kite Pharma has announced plans to open a new CAR-T manufacturing facility in Frederick County, Maryland (US). …

Latest content